Baris-Ozer/iStock via Getty Images
- Announcing preliminary financial results for its third quarter that ended Sept. 30, Sarepta Therapeutics (NASDAQ:SRPT) says its net product revenues could reach approximately $166.9M indicating a ~37.5% growth from the…
